Table 3.
Meta results for the association between HIF-1α expression and endometrial cancer.
| Characteristics (Negative vs Positive) | Studies | Pooled OR (95% CI) | P | Heterogeneity | Begg’s test | Egger’s test | |||
|---|---|---|---|---|---|---|---|---|---|
| I2 (%) | P | Z | P | T | P | ||||
| Risk (Overall) | 9 | 15.79 (8.44, 29.52) | <0.05 | 50.50% | 0.04 | 1.15 | 0.25 | 0.99 | 0.36 |
| Risk (Asian) | 8 | 14.08 (7.82, 25.35) | <0.05 | 45.30% | 0.08 | 0.37 | 0.71 | 0.38 | 0.72 |
| Tumor grade (Overall) (G1 vs G2, G3) | 15 | 1.78 (0.97, 3.26) | >0.05 | 74.70% | 0.00 | 0.99 | 0.32 | -0.57 | 0.58 |
| Tumor grade (Caucasian) (G1 vs G2, G3) | 4 | 3.09 (1.63, 5.85) | <0.05 | 14.10% | 0.32 | 0.31 | 0.75 | -0.38 | 0.47 |
| Tumor grade (Asian) (G1 vs G2, G3) | 9 | 1.21 (0.50, 2.91) | <0.05 | 80.30% | 0.00 | 1.70 | 0.09 | -6.09 | 0.03 |
| Lymph node metastasis (Overall) (N0 vs N1) | 12 | 3.25 (1.78, 5.92) | <0.05 | 63.00% | 0.00 | 1.99 | 0.05 | 2.64 | 0.03 |
| Lymph node metastasis (Caucasian) (N0 vs N1) | 2 | 1.42 (0.79, 2.56) | >0.05 | 38.70% | 0.20 | 0.00 | 1.00 | – | – |
| Lymph node metastasis (Asian) (N0 vs N1) | 8 | 3.99 (1.84, 8.65) | <0.05 | 59.00% | 0.02 | 2.10 | 0.04 | 1.08 | 0.32 |
| TNM stage (Overall) (T1 vs T2-T4) | 13 | 1.46 (0.91, 2.35) | >0.05 | 62.80% | 0.00 | 1.53 | 0.13 | 2.01 | 0.07 |
| TNM stage (Caucasian) (T1 vs T2-T4) | 7 | 1.35 (0.67, 2.70)) | >0.05 | 74.10% | 0.00 | 1.20 | 0.23 | 1.45 | 0.21 |
| TNM stage (Asian) (T1 vs T2-T4) | 5 | 1.27 (0.76, 2.13) | >0.05 | 6.40% | 6.40 | 0.73 | 0.46 | 1.02 | 0.38 |
| FIGO ((Ⅰ+Ⅱ) vs (Ⅲ+Ⅳ)) | 8 | 2.88 (0.89, 8.03) | >0.05 | 88.90% | 0.00 | 0.87 | 0.39 | 1.11 | 0.31 |
| FIGO ((Ⅰ+Ⅱ) vs (Ⅲ+Ⅳ)) (Caucasians) | 3 | 3.38 (0.50, 22.77) | >0.05 | 95.00% | 0.00 | 1.04 | 0.30 | 2.55 | 0.24 |
| FIGO ((Ⅰ+Ⅱ) vs (Ⅲ+Ⅳ)) (Asians) | 4 | 2.38 (0.35, 16.02) | >0.05 | 85.50% | 0.00 | -0.34 | 1.00 | -0.33 | 0.77 |
| Myometrial invasion (<50% vs >50%) | 11 | 2.26 (1.70, 3.01) | <0.05 | 39.70% | 0.08 | 1.71 | 0.09 | 2.81 | 0.02 |
| Myometrial invasion (Caucasian) (<50% vs >50%) | 3 | 1.18 (0.75, 1.86) | >0.05 | 0.00% | 0.93 | 1.04 | 0.30 | 7.14 | 0.09 |
| Myometrial invasion (Asian) (<50% vs >50%) | 6 | 3.30 (2.15, 5.08) | <0.05 | 0.00% | 0.55 | 0.75 | 0.45 | 1.26 | 0.28 |
| PR | 3 | 1.59 (0.29, 8.69) | >0.05 | 91.10% | 0.00 | 0.00 | 1.00 | 1.80 | 0.32 |
| ER | 3 | 0.92 (0.28, 3.03) | >0.05 | 79.40% | 0.01 | 1.04 | 0.30 | 1.93 | 0.30 |
| Recurrence | 3 | 2.71 (0.74,9.99) | >0.05 | 73.00% | 0.03 | 1.04 | 0.30 | 21.95 | 0.03 |
| Type1 vs Type2 | 4 | 1.38 (0.19, 9.84) | >0.05 | 93.70% | 0.00 | -0.34 | 1.00 | -0.03 | 0.98 |
| Pooled HR (95% CI) | |||||||||
| OS | 6 | 2.29 (1.68, 2.90) | <0.05 | 0% | 0.613 | 0.38 | 0.707 | 0.06 | 0.955 |
| OS in Caucasians | 4 | 2.07 (1.41, 2.73) | <0.05 | 0% | 0.92 | 0.34 | 0.734 | 0.05 | 0.964 |
| OS in Asians | 1 | 3.79 (2.18, 6.35) | <0.05 | – | – | – | – | – | – |
OR, odds ratio; CI, confidence interval; OS, overall survival.